NUVL vs. PRGO, ALPN, ALKS, MDGL, OGN, BBIO, INSM, PBH, RARE, and APLS
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Perrigo (PRGO), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Insmed (INSM), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Nuvalent (NASDAQ:NUVL) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Nuvalent has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Perrigo has higher revenue and earnings than Nuvalent. Perrigo is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
In the previous week, Perrigo had 17 more articles in the media than Nuvalent. MarketBeat recorded 24 mentions for Perrigo and 7 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.61 beat Perrigo's score of 0.48 indicating that Nuvalent is being referred to more favorably in the media.
Perrigo received 738 more outperform votes than Nuvalent when rated by MarketBeat users. However, 70.59% of users gave Nuvalent an outperform vote while only 66.73% of users gave Perrigo an outperform vote.
97.3% of Nuvalent shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 14.8% of Nuvalent shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Nuvalent has a net margin of 0.00% compared to Perrigo's net margin of -0.27%. Perrigo's return on equity of 7.34% beat Nuvalent's return on equity.
Nuvalent presently has a consensus price target of $90.78, suggesting a potential upside of 34.41%. Perrigo has a consensus price target of $40.67, suggesting a potential upside of 30.72%. Given Nuvalent's higher possible upside, research analysts clearly believe Nuvalent is more favorable than Perrigo.
Summary
Nuvalent beats Perrigo on 9 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
